Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma

Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor’s intrinsic resistance to therapy. Here we review our c...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Joyce K., Bednar, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715475/
https://www.ncbi.nlm.nih.gov/pubmed/34968245
http://dx.doi.org/10.3390/epigenomes5040020
_version_ 1784624135883718656
author Thompson, Joyce K.
Bednar, Filip
author_facet Thompson, Joyce K.
Bednar, Filip
author_sort Thompson, Joyce K.
collection PubMed
description Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor’s intrinsic resistance to therapy. Here we review our current understanding of epigenetic dysregulation in pancreatic cancer and how it is contributing to our efforts in early diagnosis, predictive and prognostic biomarker development and new therapeutic approaches in this deadly cancer.
format Online
Article
Text
id pubmed-8715475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87154752021-12-30 Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma Thompson, Joyce K. Bednar, Filip Epigenomes Review Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor’s intrinsic resistance to therapy. Here we review our current understanding of epigenetic dysregulation in pancreatic cancer and how it is contributing to our efforts in early diagnosis, predictive and prognostic biomarker development and new therapeutic approaches in this deadly cancer. MDPI 2021-09-27 /pmc/articles/PMC8715475/ /pubmed/34968245 http://dx.doi.org/10.3390/epigenomes5040020 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Thompson, Joyce K.
Bednar, Filip
Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title_full Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title_fullStr Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title_full_unstemmed Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title_short Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
title_sort clinical utility of epigenetic changes in pancreatic adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715475/
https://www.ncbi.nlm.nih.gov/pubmed/34968245
http://dx.doi.org/10.3390/epigenomes5040020
work_keys_str_mv AT thompsonjoycek clinicalutilityofepigeneticchangesinpancreaticadenocarcinoma
AT bednarfilip clinicalutilityofepigeneticchangesinpancreaticadenocarcinoma

Ejemplares similares